Navigation Links
Pharmacyclics Reports First Quarter 2013 Results
Date:5/1/2013

) in Patients with CD20-Positive B-Cell Non-Hodgkin Lymphoma (NHL)
Date/Time: June 15, 2013, 5:45PM-7:00PM, Location: Poster Hall, Author: Dr. Anas Younes

International Conference on Malignant Lymphoma in Lugano, Switzerland June 19-22, 2013At the International Conference on Malignant Lymphoma (ICML) there will be three oral presentations and three poster presentations on ibrutinib, and one oral presentation on abexinostat, Pharmacyclics' HDAC inhibitor. One oral presentation in the plenary session will show results using ibrutinib as a monotherapy in R/R CLL patients with deletion 17p as previously reported at AACR earlier this year. One oral presentation will cover the trial results using ibrutinib as a monotherapy in R/R Waldenstrom Macroglobulinemia (WM) patients. The other oral presentation will show the Phase I results using R-CHOP plus ibrutinib in frontline NHL patients similar to the data that will be presented at ASCO and EHA in June, 2013. Two posters are updates from the MD Anderson trial using ibrutinib plus rituximab in high risk CLL patients. An additional poster will show updated results from Pharmacyclics' trial PCYC-1104 with similar data from the oral presentation at EHA in June, 2013. An additional oral presentation will show trial data using the HDAC inhibitor abexinostat in patients with R/R follicular lymphoma.

  • Oral Presentation in Plenary Session (Encore from AACR)
    Single Agent Ibrutinib (PCI-32765) is Highly Effective in Chronic Lymphocytic Leukemia (CLL) Patients with 17p Deletion
    Date/Time: June 19, 2013, 2:40PM – 3:00PM, Locations: Room A, B and Marquee Parco Ciani, Author: Dr. Adrian Wiestner 
  • Oral Presentation
    A Prospective, Multicenter, Phase II Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Patients with Relapsed and Refractory Waldenstrom's Macroglobulinemia 
    Date/Time: June 20, 2013, 4:20PM - 4:35PM, Location: Room A and Marquee, Author: Dr. Stev
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

    Related medicine technology :

    1. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
    2. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
    3. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
    4. Pharmacyclics, Inc. Prices Public Offering of Common Stock
    5. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
    6. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
    7. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
    8. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
    9. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
    10. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
    11. Hospira Reports First-Quarter 2013 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/17/2014)... -- Revenue and earnings above the previous year ... In the past 2013/14 fiscal year (ended 30 ... EUR 4.287 billion (last year: EUR 4.190 billion) despite unfavorable ... 360 million. "Overall, 2013/14 was a successful fiscal year for ... and CEO of Carl Zeiss AG. "Thanks to our broad ...
    (Date:12/17/2014)... With advancements in neurological and functional ... seeing new growth, according to Kalorama Information. Though ... the majority of market volume, newer 3T systems ... are creating opportunities for more sophisticated applications. The medical ... a rate of 4%, with world market revenues ...
    (Date:12/17/2014)... , Dec. 17, 2014  ImmunoCellular Therapeutics, Ltd. ... Patent and Trademark Office (USPTO) has issued a ... dendritic cell-based immunotherapeutic vaccine targeting six tumor antigens ... of US Patent No. 8,871,211, which issued October ... by administering a dendritic cell composition comprising peptide ...
    Breaking Medicine Technology:ZEISS Asserts its Position in Difficult Environment 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2
    ... studies of immunosuppression in kidney transplant ... Aug. 28 "Cylex, Inc., in association,with our Korean ... to,announce our support for a major, multi-center trial of ... medical institutions,in the Republic of Korea," stated Brad Stewart, ...
    ... - Results Further Support the Clinical Profile of ... Survival of Patients,With Hormone Refractory Prostate Cancer (HRPC), ... therapeutics company,today announced that the primary objective of ... The study showed that even single doses of,Alpharadin ...
    Cached Medicine Technology:Cylex Announces Plan for Multi-Center Trial of ImmuKnow(R) Assay in South Korea 2Cylex Announces Plan for Multi-Center Trial of ImmuKnow(R) Assay in South Korea 3Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin 2Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin 3Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin 4
    (Date:12/19/2014)... December 19, 2014 The Hermitage ... club in Southern Vermont’s Deerfield Valley, announced today that ... by classic rock songs. , Three time Grammy ... a private concert followed by a trail naming ceremony. ... trail names include: “I’m Alright” the theme song for ...
    (Date:12/19/2014)... A new study suggests a possible link between certain ... night sweats -- and higher rates of hip fractures ... menopause, affecting about 60 percent of women. The hormonal ... they then face a higher risk of weakened bones ... moderate or severe menopausal symptoms are more likely to ...
    (Date:12/19/2014)... HealthDay Reporter THURSDAY, Dec. 18, 2014 (HealthDay ... high levels of air pollution late in pregnancy may have ... Researchers found that of nearly 1,800 U.S. women who ... most air pollution during pregnancy were twice as likely to ... the third trimester, specifically, showed the strongest correlation to autism ...
    (Date:12/19/2014)... News) -- Traveling through the same U.S. airport gate, ... others within a four-hour time span, illustrating just how ... "The exposures in this report were not prolonged ... terminal, highlighting the fact that measles is highly contagious," ... disease specialist at the U.S. Centers for Disease Control ...
    (Date:12/19/2014)... Reinberg HealthDay Reporter THURSDAY, ... on one leg for at least 20 seconds you may ... Difficulty standing on one leg may indicate that small strokes ... for more serious strokes is high, the investigators reported online ... showing instability while standing on one leg, as well as ...
    Breaking Medicine News(10 mins):Health News:The Hermitage Club Officially Names Four Ski Trails after Iconic Rock Songs by Grammy Award Winner Kenny Loggins 2Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 3Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Can You Balance on One Leg? You May Have Lower Stroke Risk 2
    ... Jerry A. Boriskin of University of the Rockies Delivers ... when many military men and women are returning home ... member of the University of the Rockies and author ... to recognize and prevent post traumatic stress disorder (PTSD) ...
    ... Calif., Feb. 20 CUREXO Technology Corporation, pioneer ... robotic products for orthopaedic applications, which is focused ... it has submitted a premarket notification 510(k) application ... for market clearance in the U.S. for use ...
    ... Executive to Head Company,s Network of International Subsidiaries and ... (Nasdaq: CYNO ), a leading developer and ... systems, today announced the appointment of William T. Kelley ... will be responsible for the company,s direct subsidiaries in ...
    ... apt to die early, study finds, , , WEDNESDAY, Feb. 25 ... risk of premature death in adulthood as much as smoking ... , Dr. Martin Neovius of the Karolinska Institute and ... military conscription tests in which their body mass index (BMI) ...
    ... re-alignment of shared services, including Business Technology, ... Device Governance CommitteesROCKVILLE, Md. and PRINCETON, N.J., ... (OAPI) and Otsuka Pharmaceutical Development & Commercialization, ... part of the North American pharmaceutical organizations, ...
    ... CROSSFIT TRAINER ANDY PETRANEK TO TACKLE THE HOTTEST TREND ... medalist to the growing list of female athletes who ... is part of a burgeoning movement of professional female ... grueling, high-intensity workouts used to train the warrior actors ...
    Cached Medicine News:Health News:Leading Cause of Stress to Military War Veterans Key Topic at 35th Advanced International Winter Symposium 2Health News:Leading Cause of Stress to Military War Veterans Key Topic at 35th Advanced International Winter Symposium 3Health News:CUREXO Technology Corporation Announces 510(k) Submission to FDA for Total Knee Arthroplasty Application 2Health News:Cynosure Appoints William T. Kelley as Senior Vice President of International Sales 2Health News:Cynosure Appoints William T. Kelley as Senior Vice President of International Sales 3Health News:Obesity Just as Risky for Teens as Heavy Smoking 2Health News:Otsuka America Pharmaceutical, Inc. and Otsuka Pharmaceutical Development & Commercialization, Inc. Announce Restructuring Changes Aimed at Growing Otsuka's Pharmaceutical Business Worldwide 2Health News:Otsuka America Pharmaceutical, Inc. and Otsuka Pharmaceutical Development & Commercialization, Inc. Announce Restructuring Changes Aimed at Growing Otsuka's Pharmaceutical Business Worldwide 3Health News:CrossFit: A Workout Fit for an Olympian 2
    ... Cochrane Reviews enable all those involved with ... with the very latest evidence in their ... becomes harder each year as the volume ... problem by delivering the best single source ...
    Over 10,000 entries. This dictionary is both a home medical guide and as an aid for all those working in the medical and allied professions. The entries are laid out and jargon-free....
    ... for PDA is a combination of the Medical ... Dictionary pocket for PDA. The first part of ... overview of the Spanish language, i.e. pronunciation, common ... of anatomy and medical terminology. The second part ...
    Taber's Cyclopedic Medical Dictionary is published by F.A. Davis. Contains approximately 56,000 terms....
    Medicine Products: